BIOA — BioAge Labs, Inc

BioAge Labs, Inc (BIOA) is a drug manufacturers - specialty & generic company listed on NASDAQ. It is led by Kristen Fortney Ph.D., based in 5885 Hollis Street, EmeryVille, CA, United States, 94608, with about 60 employees. BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Latest reported BIOA revenue for 2025-09-30 was $2.1M. Net income was -$54.7M. Revenue was down 14.8% from 2025-06-30 to 2025-09-30. BIOA currently screens at market cap $697.9M.

Use this BIOA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the BIOA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the BIOA SEC filings page. Lician reads the product cache first so this HTML stays unique to BioAge Labs, Inc even when a live quote feed is slow.